PL3645551T3 - Zrekombinowane wektory wirusowe o zmodyfikowanym tropizmie i ich zastosowania do celowanego wprowadzania materiału genetycznego do komórek ludzkich - Google Patents

Zrekombinowane wektory wirusowe o zmodyfikowanym tropizmie i ich zastosowania do celowanego wprowadzania materiału genetycznego do komórek ludzkich

Info

Publication number: PL3645551T3
Authority: PL; Poland
Prior art keywords: tropism; viral vectors; human cells; genetic material; recombinant viral
Prior art date: 2017-06-27

Application number

PL18749635.1T

Other languages

English (en)

Inventor

Christos Kyratsous

Andrew J. Murphy

Cheng Wang

Leah SABIN

Original Assignee

Regeneron Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-27

Filing date

2018-06-27

Publication date

2024-07-01

2018-06-27 Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.

2024-07-01 Publication of PL3645551T3 publication Critical patent/PL3645551T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Virology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL18749635.1T 2017-06-27 2018-06-27 Zrekombinowane wektory wirusowe o zmodyfikowanym tropizmie i ich zastosowania do celowanego wprowadzania materiału genetycznego do komórek ludzkich PL3645551T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762525704P	2017-06-27	2017-06-27
PCT/US2018/039874 WO2019006043A1 (en)	2017-06-27	2018-06-27	RECOMBINANT VIRAL VECTORS WITH MODIFIED TROPISM AND USES THEREOF FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS

Publications (1)

Publication Number	Publication Date
PL3645551T3 true PL3645551T3 (pl)	2024-07-01

Family

ID=63080487

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18749635.1T PL3645551T3 (pl)	2017-06-27	2018-06-27	Zrekombinowane wektory wirusowe o zmodyfikowanym tropizmie i ich zastosowania do celowanego wprowadzania materiału genetycznego do komórek ludzkich

Country Status (29)

Country	Link
US (1)	US20200140491A1 (pl)
EP (2)	EP4372008A3 (pl)
JP (4)	JP7372154B2 (pl)
KR (3)	KR20250160215A (pl)
CN (2)	CN110799524A (pl)
AU (3)	AU2018290882B2 (pl)
BR (1)	BR112019027854A2 (pl)
CA (1)	CA3066947A1 (pl)
CL (3)	CL2019003842A1 (pl)
CO (1)	CO2019014683A2 (pl)
DK (1)	DK3645551T5 (pl)
ES (1)	ES2978295T3 (pl)
FI (1)	FI3645551T3 (pl)
HR (1)	HRP20240773T1 (pl)
HU (1)	HUE066398T2 (pl)
IL (2)	IL271573B2 (pl)
LT (1)	LT3645551T (pl)
MA (1)	MA49513B1 (pl)
MD (1)	MD3645551T2 (pl)
MX (2)	MX2020000244A (pl)
PE (1)	PE20200488A1 (pl)
PH (1)	PH12019550266A1 (pl)
PL (1)	PL3645551T3 (pl)
PT (1)	PT3645551T (pl)
RS (1)	RS65569B1 (pl)
SG (1)	SG11201911610TA (pl)
SI (1)	SI3645551T1 (pl)
SM (1)	SMT202400189T1 (pl)
WO (1)	WO2019006043A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2018338728B2 (en)	2017-09-29	2025-01-02	Centre National De La Recherche Scientifique (Cnrs)	Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
EP3856762A1 (en)	2018-09-28	2021-08-04	Voyager Therapeutics, Inc.	Frataxin expression constructs having engineered promoters and methods of use thereof
CN119684417A (zh)	2018-10-02	2025-03-25	沃雅戈治疗公司	重新定向aav衣壳的嗜性
EP3736330A1 (en) *	2019-05-08	2020-11-11	European Molecular Biology Laboratory	Modified adeno-associated virus (aav) particles for gene therapy
PH12021552887A1 (en)	2019-05-24	2022-09-05	Regeneron Pharma	Modified viral particles and uses thereof
IL298001A (en)	2020-05-13	2023-01-01	Voyager Therapeutics Inc	Redirecting tropism of adeno-associated virus capsids
AU2021378075B2 (en)	2020-11-11	2025-03-27	Borea Therapeutics S.R.L.	Modified viral particles for gene therapy
CN115873987A (zh) *	2021-09-30	2023-03-31	北京五加和基因科技有限公司	检测腺相关病毒载体感染滴度的方法和试剂盒
WO2023081648A1 (en)	2021-11-02	2023-05-11	Voyager Therapeutics, Inc.	Aav capsid variants and uses thereof
WO2023081850A1 (en)	2021-11-04	2023-05-11	Regeneron Pharmaceuticals, Inc.	Viral particles retargeted to skeletal muscle
CN114213505B (zh) *	2021-12-10	2022-09-20	和元生物技术（上海）股份有限公司	一种适用于特异感染u87-mg细胞的腺相关病毒突变体
CN119095866A (zh) *	2022-02-22	2024-12-06	北卡罗来纳大学查佩尔希尔分校	嵌合神经向性aav衣壳
CN115044615B (zh) *	2022-04-28	2025-09-05	三峡大学	一种靶向感染乳腺癌细胞的aav载体及应用
WO2023220603A1 (en)	2022-05-09	2023-11-16	Regeneron Pharmaceuticals, Inc.	Vectors and methods for in vivo antibody production
EP4522631A1 (en) *	2022-05-13	2025-03-19	Children's Medical Research Institute	Adeno-associated virus capsids
JP2025525792A (ja)	2022-07-29	2025-08-07	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	トランスフェリン受容体１に対して再標的化されるウイルス粒子
WO2024107765A2 (en)	2022-11-14	2024-05-23	Regeneron Pharmaceuticals, Inc.	Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
EP4634220A2 (en) *	2022-12-16	2025-10-22	Regeneron Pharmaceuticals, Inc.	Antigen-binding molecules that bind to aav particles and uses
WO2024131982A1 (zh) *	2022-12-23	2024-06-27	北京大学宁波海洋药物研究院	衣壳蛋白-抗体偶联物、修饰的病毒、药物组合和用途
KR20250150011A (ko)	2023-02-13	2025-10-17	리제너론 파마슈티칼스 인코포레이티드	항-인간 cacng1 항체를 이용한 근육 관련 장애 치료
AU2024265507A1 (en)	2023-05-02	2025-10-30	Regeneron Pharmaceuticals, Inc.	Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
CN118955652A (zh) *	2023-05-15	2024-11-15	杭州新昶基因技术有限公司	腺相关病毒衣壳蛋白、包含其的腺相关病毒及应用
WO2025042428A1 (en) *	2023-08-18	2025-02-27	Regeneron Pharmaceuticals, Inc.	Bispecific antigen-binding molecules and uses thereof
WO2025072501A2 (en) *	2023-09-26	2025-04-03	The Trustees Of Princeton University	Method for converting farnesyl pyrophosphate synthase into a geranyl pyrophosphate synthase
WO2025151796A1 (en)	2024-01-11	2025-07-17	Regeneron Pharmaceuticals, Inc.	Viral particles retargeted to nervous system tissues
US20250242018A1 (en)	2024-01-26	2025-07-31	Regeneron Pharmaceuticals, Inc.	Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184603A2 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2026025058A1 (en)	2024-07-25	2026-01-29	Regeneron Pharmaceuticals, Inc.	Aav viral particles retargeted to egfr-expressing cancer cells
WO2026039325A2 (en)	2024-08-12	2026-02-19	Regeneron Pharmaceuticals, Inc.	Modified mtm1 genes and uses thereof
CN119039401B (zh) *	2024-08-19	2025-04-11	广州派真生物技术有限公司	腺相关病毒突变体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2224907A1 (en)	1995-07-25	1997-02-13	Introgene B.V.	Methods and means for targeted gene delivery
JP2002507391A (ja)	1998-02-06	2002-03-12	ザユーエイビーリサーチファンデイション	繊維ノブのｈｉループに異種ペプチドエピトープを含有するアデノウイルスベクター
DE19849643A1 (de) *	1998-10-29	2000-05-04	Deutsches Krebsforsch	An das AAV-Kapsid bindender, den Zelltropismus verändernder Antikörper und Verfahren zum gerichteten Gentransfer
DE19933719A1 (de)	1999-07-19	2001-01-25	Medigene Ag	Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung
AU2003270619A1 (en) *	2002-09-12	2004-04-30	Molecular Probes, Inc.	Site-specific labeling of affinity tags in fusion proteins
US7273835B2 (en) *	2004-08-04	2007-09-25	Honeywell International Inc.	Azeotrope-like compositions of difluoromethane
US9963510B2 (en)	2005-04-15	2018-05-08	Macrogenics, Inc.	Covalent diabodies and uses thereof
EP3479844B1 (en)	2005-04-15	2023-11-22	MacroGenics, Inc.	Covalent diabodies and uses thereof
US20100203083A1 (en)	2007-05-31	2010-08-12	Medigene Ag	Mutated structural protein of a parvovirus
EP2012122A1 (en)	2007-07-06	2009-01-07	Medigene AG	Mutated parvovirus structural proteins as vaccines
KR101747103B1 (ko)	2009-06-26	2017-06-14	리제너론 파마슈티칼스 인코포레이티드	천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
WO2011072204A1 (en)	2009-12-10	2011-06-16	Regeneron Pharmaceuticals, Inc.	Mice that make heavy chain antibodies
FR2955773B1 (fr) *	2010-02-01	2017-05-26	Commissariat Energie Atomique	Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
US20150203591A1 (en)	2012-08-02	2015-07-23	Regeneron Pharmaceuticals, Inc.	Mutivalent antigen-binding proteins
EP2999791B1 (en) *	2013-05-21	2018-12-05	University of Florida Research Foundation, Inc.	Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer
SG10201808225TA (en)	2014-03-21	2018-10-30	Regeneron Pharma	Non-human animals that make single domain binding proteins
WO2016054554A1 (en) *	2014-10-03	2016-04-07	University Of Massachusetts	Heterologous targeting peptide grafted aavs
DE102015207516A1 (de) *	2015-04-23	2016-10-27	Paul-Ehrlich-Institut Bundesamt Für Sera Und Impfstoffe	Kopplung von Proteinen von Interesse (POI) mit viralen Vektoren mittels Intein-vermittelten Proteinspleißens

2018
- 2018-06-27 CN CN201880042990.1A patent/CN110799524A/zh active Pending
- 2018-06-27 SM SM20240189T patent/SMT202400189T1/it unknown
- 2018-06-27 MD MDE20200492T patent/MD3645551T2/ro unknown
- 2018-06-27 CA CA3066947A patent/CA3066947A1/en active Pending
- 2018-06-27 PE PE2019002652A patent/PE20200488A1/es unknown
- 2018-06-27 MA MA49513A patent/MA49513B1/fr unknown
- 2018-06-27 EP EP24154743.9A patent/EP4372008A3/en active Pending
- 2018-06-27 JP JP2019572024A patent/JP7372154B2/ja active Active
- 2018-06-27 AU AU2018290882A patent/AU2018290882B2/en active Active
- 2018-06-27 ES ES18749635T patent/ES2978295T3/es active Active
- 2018-06-27 DK DK18749635.1T patent/DK3645551T5/da active
- 2018-06-27 BR BR112019027854-0A patent/BR112019027854A2/pt active Search and Examination
- 2018-06-27 IL IL271573A patent/IL271573B2/en unknown
- 2018-06-27 SG SG11201911610TA patent/SG11201911610TA/en unknown
- 2018-06-27 PT PT187496351T patent/PT3645551T/pt unknown
- 2018-06-27 MX MX2020000244A patent/MX2020000244A/es unknown
- 2018-06-27 PL PL18749635.1T patent/PL3645551T3/pl unknown
- 2018-06-27 RS RS20240615A patent/RS65569B1/sr unknown
- 2018-06-27 HR HRP20240773TT patent/HRP20240773T1/hr unknown
- 2018-06-27 EP EP18749635.1A patent/EP3645551B1/en active Active
- 2018-06-27 LT LTEPPCT/US2018/039874T patent/LT3645551T/lt unknown
- 2018-06-27 HU HUE18749635A patent/HUE066398T2/hu unknown
- 2018-06-27 KR KR1020257035498A patent/KR20250160215A/ko active Pending
- 2018-06-27 KR KR1020207001282A patent/KR102714347B1/ko active Active
- 2018-06-27 SI SI201831093T patent/SI3645551T1/sl unknown
- 2018-06-27 FI FIEP18749635.1T patent/FI3645551T3/fi active
- 2018-06-27 IL IL317938A patent/IL317938A/en unknown
- 2018-06-27 CN CN202310920054.9A patent/CN117051045B/zh active Active
- 2018-06-27 KR KR1020247032850A patent/KR102877478B1/ko active Active
- 2018-06-27 WO PCT/US2018/039874 patent/WO2019006043A1/en not_active Ceased
- 2018-06-27 US US16/625,189 patent/US20200140491A1/en active Pending
2019
- 2019-12-05 PH PH12019550266A patent/PH12019550266A1/en unknown
- 2019-12-24 CO CONC2019/0014683A patent/CO2019014683A2/es unknown
- 2019-12-26 CL CL2019003842A patent/CL2019003842A1/es unknown
2020
- 2020-01-08 MX MX2023009050A patent/MX2023009050A/es unknown
- 2020-12-22 CL CL2020003343A patent/CL2020003343A1/es unknown
2022
- 2022-10-11 JP JP2022163041A patent/JP2022183228A/ja active Pending
2023
- 2023-07-19 AU AU2023206143A patent/AU2023206143B2/en active Active
2024
- 2024-02-08 JP JP2024017826A patent/JP2024036644A/ja active Pending
- 2024-05-07 CL CL2024001376A patent/CL2024001376A1/es unknown
2026
- 2026-01-07 JP JP2026001735A patent/JP2026042952A/ja active Pending
- 2026-01-23 AU AU2026200511A patent/AU2026200511A1/en active Pending

Also Published As

Publication number	Publication date
AU2018290882B2 (en)	2023-07-27
MD3645551T2 (ro)	2024-08-31
IL271573A (en)	2020-02-27
PH12019550266A1 (en)	2021-01-11
JP2026042952A (ja)	2026-03-11
EP4372008A2 (en)	2024-05-22
AU2023206143A1 (en)	2023-08-10
KR102714347B1 (ko)	2024-10-14
AU2026200511A1 (en)	2026-02-12
CL2024001376A1 (es)	2024-10-25
IL317938A (en)	2025-02-01
EP3645551A1 (en)	2020-05-06
BR122023021213A2 (pt)	2024-02-20
IL271573B1 (en)	2025-02-01
KR20250160215A (ko)	2025-11-11
US20200140491A1 (en)	2020-05-07
MA49513B1 (fr)	2024-05-31
RS65569B1 (sr)	2024-06-28
HUE066398T2 (hu)	2024-07-28
KR20200022434A (ko)	2020-03-03
KR102877478B1 (ko)	2025-10-29
CL2020003343A1 (es)	2021-06-25
KR20240149451A (ko)	2024-10-14
CN110799524A (zh)	2020-02-14
MX2020000244A (es)	2020-09-28
CN117051045A (zh)	2023-11-14
DK3645551T5 (da)	2024-08-26
SMT202400189T1 (it)	2024-07-09
CA3066947A1 (en)	2019-01-03
RU2020101279A (ru)	2021-07-27
JP2024036644A (ja)	2024-03-15
DK3645551T3 (da)	2024-05-06
EP4372008A3 (en)	2024-07-31
ES2978295T3 (es)	2024-09-10
MX2023009050A (es)	2023-08-10
SG11201911610TA (en)	2020-01-30
AU2018290882A1 (en)	2020-01-16
IL271573B2 (en)	2025-06-01
RU2020101279A3 (pl)	2022-02-04
FI3645551T3 (fi)	2024-05-03
WO2019006043A1 (en)	2019-01-03
JP7372154B2 (ja)	2023-10-31
CL2019003842A1 (es)	2020-07-24
PE20200488A1 (es)	2020-03-03
CN117051045B (zh)	2025-04-08
LT3645551T (lt)	2024-05-10
CO2019014683A2 (es)	2020-01-17
AU2023206143B2 (en)	2025-10-30
JP2022183228A (ja)	2022-12-08
BR112019027854A2 (pt)	2020-07-07
PT3645551T (pt)	2024-05-13
MA49513A (fr)	2020-05-06
HRP20240773T1 (hr)	2024-09-13
JP2020529196A (ja)	2020-10-08
EP3645551B1 (en)	2024-03-13
SI3645551T1 (sl)	2024-06-28

Publication	Publication Date	Title
IL271573A (en)	2020-02-27	Recombinant viral vectors that have undergone a tropism change and their uses for the targeted introduction of genetic material into human cells
IL271570A (en)	2020-02-27	Recombinant viral particles that have undergone a tropism change and their uses for the targeted introduction of genetic material into human cells
IL266045A (en)	2019-06-30	Proteins change from secretable immunomodulators and transgenic cell therapy
IL271993A (en)	2020-02-27	Viral vectors of cell lysis and their uses
SG11201911603SA (en)	2020-01-30	ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
IL273362A (en)	2020-05-31	Carriers of DNA that do not undergo integration for genetic modification of cells
IL259141A (en)	2018-06-28	Modified friedreich ataxia genes and vectors for gene therapy
SG11202009009UA (en)	2020-10-29	Viral and non-viral nanoplasmid vectors with improved production
ZA201708638B (en)	2019-08-28	Prrsv minor protein¿containing recombinant viral vectors and methods of making and use thereof
ZA201905372B (en)	2021-01-27	Therapeutic and neuroprotective peptides
ZA202000595B (en)	2021-04-28	Novel therapeutic enzyme fusion protein and use thereof
IL275951A (en)	2020-08-31	Vectors that evade the immune system and their use for gene therapy
GB2573931B (en)	2022-01-26	Electrode material and application thereof
ZA201904386B (en)	2023-01-25	S-arrestin peptides and therapeutic uses thereof
HK40039553A (en)	2021-07-16	Modified viral vectors and methods of making and using the same
HK40005456A (en)	2020-05-08	Secretable variant immunomodulatory proteins and engineered cell therapy